Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum–phosphato complexes towards human ovarian cancer cells
- 25 November 2008
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (47) , 18314-18319
Abstract
DNA is believed to be the molecular target for the cytotoxic activities of platinum (Pt) anticancer drugs. We report here a class of platinum(II)- and platinum(IV)-pyrophosphato complexes that exhibit cytotoxicity comparable with and, in some cases, better than cisplatin in ovarian cell lines (A2780, A2780/C30, and CHO), yet they do not show any evidence of covalent binding to DNA. Moreover, some of these compounds are quite effective in cisplatin- and carboplatin-resistant cell line A2780/C30. The lack of DNA binding was demonstrated by the absence of a detectable Pt signal by atomic absorption spectroscopy using isolated DNA from human ovarian cells treated with a platinum(II)-pyrophosphato complex, ( trans -1,2-cyclohexanediamine)(dihydrogen pyrophosphato) platinum(II), (pyrodach-2) and from NMR experiments using a variety of nucleotides including single- and double-stranded DNA. Furthermore, pyrodach-2 exhibited reduced cellular accumulations compared with cisplatin in cisplatin- and carboplatin-resistant human ovarian cells, yet the IC 50 value for the pyrophosphato complex was much less than that of cisplatin. Moreover, unlike cisplatin, pyrodach-2 treated cells overexpressed fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Data presented in this report collectively indicate that pyrodach-2 follows different cytotoxic mechanisms than does cisplatin. Unlike cisplatin, pyrodach-2 does not undergo aquation during 1 week and is quite soluble and stable in aqueous solutions. Results presented in this article represent a clear paradigm shift not only in expanding the molecular targets for Pt anticancer drugs but also in strategic development for more effective anticancer drugs.Keywords
This publication has 41 references indexed in Scilit:
- Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the MitochondrionCancer Research, 2007
- Cisplatin-Induced Apoptosis Involves Membrane Fluidification via Inhibition of NHE1 in Human Colon Cancer CellsCancer Research, 2007
- Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathwaysProceedings of the National Academy of Sciences, 2007
- Modification and Uptake of a Cisplatin Carbonato Complex by Jurkat CellsMolecular Pharmacology, 2006
- Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/ GEM®640Annals of the New York Academy of Sciences, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- In vitro studies on the mechanisms of oxaliplatin resistanceCancer Chemotherapy and Pharmacology, 2001
- Kinetic analysis of the cis-diamminedichloroplatinum(II)-cysteine reaction: Implications to the extent of platinum-DNA bindingJournal of Inorganic Biochemistry, 1997
- Facile formation of a cis-platin-nonapeptide complex of human DNA polymerase-? originJournal of the Chemical Society, Chemical Communications, 1995
- Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.Journal of Clinical Investigation, 1991